A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Synthetic glycans control gut microbiome structure and mitigate colitis in mice
Nature Communications Open Access 10 March 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
19 November 2018
In the HTML version of this article initially published online, Box 1 was missing. The error has been corrected online as of 19 November 2018.
References
Fankhauser, M., Moser, C. & Nyfeler, T. Patents as early indicators of technology and investment trends: analyzing the microbiome space as a case study. Front. Bioeng. Biotechnol. 6, 84 (2018).
University of Chicago Technology Commercialization. Polsky Microbiome – Venture Funding Data. https://polsky.uchicago.edu/microbiome-research-at-uchicago/ (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.T.-O. is consultant-in-residence at Global Engage and became an advisor to the Janssen Human Microbiome Institute after completion of Microbiome Futures; M.B. serves on the scientific advisory boards of Elysium, Inc, Ubiome, Inc., Commense, Inc. and Seed, Inc.; R.B. has served as an expert witness for Kirkland and Ellis LLC, in advisory and consulting roles to the Simons Foundation, Novartis, Eli Lilly and Merus, and is currently collaborating with Novartis and Merus; P.C. is CEO and Co-Founder of General Automation Lab Technologies, Inc.; E.E. is a scientific consultant to DayTwo & BiomX; C.H. serves on the scientific advisory boards of Seres Therapeutics and Microbiome Insights; D. Kyle is an employee of, and owns shares in, Evolve BioSystems Inc.; D.L. is founder of and advisor to Vedanta, Director at Pfizer, Inc., and a recipient of research funding for microbiota projects from Boehringer Ingelheim; A. Maiti is an employee of Pfizer Inc.; A. Maue is an employee of Taconic Biosciences; B.O. is an employee of Vedanta Biosciences, a company developing drugs in the human microbiome field, and holds stock options in the company; J.E.T.v.H.V. is an employee of Chr. Hansen A/S; J.W. is founder & CEO of iCarbonX.
Rights and permissions
About this article
Cite this article
Taroncher-Oldenburg, G., Jones, S., Blaser, M. et al. Translating microbiome futures. Nat Biotechnol 36, 1037–1042 (2018). https://doi.org/10.1038/nbt.4287
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4287
This article is cited by
-
Gut Microbiota Resilience Mechanisms Against Pathogen Infection and its Role in Inflammatory Bowel Disease
Current Clinical Microbiology Reports (2023)
-
Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota
Nature Reviews Microbiology (2022)
-
Synthetic glycans control gut microbiome structure and mitigate colitis in mice
Nature Communications (2022)
-
The microbiome in SLE pathogenesis
Nature Reviews Rheumatology (2019)